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METHOD OF USING CCR3 BINDING
AGENTS TO DETECT CHOROIDAL
NEOVASCULARIZATION

wild-type mouse eyes compared to control (uninjured eyes),
and was reduced by intraocular administration of neutralizing
anti-mouse CCR3Ab compared to isotype IgG. n:6-10,
*P<0.05 compared to IgG treatment. (c) Stimulation with
eotaxins for 24 h induced human CEC proliferation. n:4,

This application is a national stage of PCT International

*P<0.05 compared to bovine serum albumin (BSA) treat
ment. (d,e) Stimulation with eotaxins, but not PBS, induced

Application No. PCT/US2010/036202, ?led May 26, 2010,
which claims priority under 35 U.S.C. 119(e) to provisional

actin polymerization in human CECs. Relative F-actin con
tent is expressed as the ratio of the mean channel ?uorescence

application No. 61/181,161, ?led May 26, 2009.

between eotaxin- and media alone-stimulated cells (d).

BACKGROUND

Rhodamine-phalloidin staining shows F-actin ?bre formation
in eotaxin-stimulated cells (e). Nuclei stained blue by DAPI.
Data representative of 3-4 independent experiments are

Age-related macular degeneration (AMD), a leading cause
of blindness worldwide, is as prevalent as cancer in industri
alized nations. Most blindness in AMD results from invasion

shown. (c,e) CCL11 (10 ng/ml), CCL24 (100 ng/ml), CCL26

of the retina by choroidal neovascularization (CNV). AMD

(2 ug/ml). (f) Stimulation with eotaxins for 16 hours induces

affects 30-50 million people globally, with approximately

dose-dependent migration of human CECs across 8 pm pore
size Transwells. n:5-10, *P<0.05 compared to BSA treat

90% of severe vision loss attributed to CNV (Ambati, 1., et al.,

Surv Ophthalmol. 48, 257-293 (2003)). The worldwide

ment. (a-c, f) Signi?cance by Mann-Whitney U test. Error

prevalence of CNV is expected to double in the next decade

bars depict s.e.m.
FIGS. 3a-j show that CNV is reduced by CCR3 or eotaxin

due to population aging. Targeting the pro-angiogenic cytok
ine vascular endothelial growth factor (VEGF)-A has been
validated in patients with CNV (Gragoudas, et al. N Engl J.
Med. 351, 2805-2816 (2004); Brown. et al. NEngl J. Med.
355, 1432-1444 (2006); Rosenfeld, et al. NEnglJ. Med. 355,
1419-1431 (2006)). However, substantial improvement of

20

ablation or blockade independent of leukocyte modulation.
(a,b) Laser-induced CNV in wild-type mice was reduced by

neutralizing anti-mouse CCR3Ab compared to isotype IgG
(a) and by the CCR3 receptor antagonist (RA) SB328437
25

(2006)) blockade of VEGF-A, which is constitutively

in drug-treated mice. (d) Laser-induced CNV was reduced in
30

CCR3_/_ mice compared to wild-type mice. n:9, *P<0.05
compared to wild-type mice. (e) Eotaxin-1 (Ccl-11) and
eotaxin-2 (Ccl-24) protein levels, measured by ELISA, were
increased following laser injury in wild-type mice. n:6,

35

CCL-24 immuno?uorescence was localized in the retinal

expressed in the normal adult human retina Famiglietti et al.
Brain Res. 969, 195-204 (2003)), are emerging Nishijima et
al., Am J Pathol. 171, 53-67 (2007); Saint-Geniez et al., PLoS
ONE. 3, e3554 (2008)). Thus, treatment strategies based on
more speci?c targeting of CNV are desirable. However, no

((S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propi
onate) compared to vehicle (PBS/DMSO) (b) in a dose-de
pendent fashion. n:8-12, *P<0.05 compared to no antibody
or receptor antagonist. (c) Representative examples of CNV

vision occurs only in one-third of patients treated with
VEGF-A antagonists, and one-sixth of treated patients still
progress to legal blindness. Moreover, safety concerns with
continual (Brown, et al. N Engl J. Med. 355, 1432-1444

*P<0.05, #P<0.01 compared to 0 h baseline. (f) CCL-11 and

pigmented epithelial cell layer (arrows) adjacent to CD31+

molecular marker speci?c for human CNV has yet been

reported.

choroidal endothelial cells (arrowheads) on day 1 after laser

injury in wild-type mice. Nuclei stained blue by DAPI. No
speci?c immuno?uorescence was detected with isotype con

BRIEF DESCRIPTION OF THE FIGURES
40

trol IgGs. Images representative of 3 independent experi

FIGS. la-j show that CCR3 and eotaxins are expressed in

ments are shown. (g) Laser-induced CNV was reduced in

choroidal neovascularization. (a,b) Immuno?uorescence
shows that CCR3 receptor expression colocalizes with
CD31+ expressing blood vessels in surgically excised human
AMD CNV tissue. Nuclei stained blue by DAPI. (b) Speci
?city of CCR3 staining is con?rmed by absence of staining
with isotype control IgG (a). (c,d) CCR3 is not immunolo
calized in CD31+ blood vessels (white arrowheads) in the
choroid of patients with atrophic AMD who do not have CNV
(c) or in aged patients without AMD (d). Auto?uorescence of

CCL11_/_ and in CCL24_/_ mice compared to wild-type
mice. n:8-10, *P<0.05 compared to wild-type mice. CNV is
further reduced in CCL 11_/_><CCL24_/_ mice compared to
single null mice. #P<0.05 compared to single null mice. (h)

45

Laser-induced CNV in wild-type mice was reduced by neu
tralizing antibodies against mouse CCL11 or CCL24 com

50

pared to isotype IgG. n:7-10, *P<0.05 compared to no injec
tion (control) or IgG. (i) Representative examples of CNV in
eotaxin-neutralized mice. (j) Neutralizing anti-CCR3 anti

retinal pigmented epithelium (white arrow) and Bruch’s

bodies (Ab) reduced laser-induced CNV in mice de?cient in

membrane (asterisks) overlying choroid is seen (c,d). (e,f)

eosinophils (Adbl GATA) or mast cells (Kitw'v). n:6-9,
*P<0.05 compared to IgG. Scale bars, (c,i), 100 um; f, 20 um.

CCR3 is not expressed in surgically excised avascular retinal
?brosis tissue (e) or in blood vessel of choroidal melanoma

(f). (g-j) Immunohistochemistry shows expression of CCL11

Error bars depict s.e.m.
55

(g), CCL24 (h), and CCL26 (i) in surgically excised AMD
CNV tissue, primarily in the stroma (arrowheads) but also in
the blood vessels (arrows). Speci?city of staining is con
?rmed by absence of staining with isotype control IgG (j).
Scale bars, 10 um.

showed normal retinal vascular ?lling, but no areas of hyper
60

FIGS. 2a-f show CCR3 activation promotes angiogenesis.
(a) Tube formation of primary human choroidal endothelial
cells (CECs) in Matrigel in vitro was reduced by neutralizing
anti-human CCR3 antibodies (Ab) compared to isotype IgG.

n:6, *P<0.05 compared to isotype IgG. (b) Fraction of
CD31+VEGFR2+ gated mouse CECs in vivo in proliferative
state (S phase) was increased 5 days after laser injury in

FIGS. 4a-g demonstrate that CCR3-targeting quantum
dots detect subretinal choroidal neovascularization (CNV).
(a) Images of the fundus taken after intravenous injection of
sodium ?uorescein in wild-type and CCL2_/_><CCRT_/_ mice

?uorescence indicative of CNV. (b) After intravenous injec
tion of QDot-CCR3 Fab in the same CCL2_/_><CCR2_/_

mouse shown in (a), focal branching choroidal hyper?uores
cence was visualized (arrow) at 1 h in the same area that was
65

not hyper?uorescent during ?uorescein angiography (arrow
head in a). The intensity of this hyper?uorescence (shown in
the inset) increased, attaining a peak at 4 h, and then declined
in intensity but still persisted at 12 h. Corresponding images

US 8,778,616 B2
4

3
of QDot-Isotype Fab angiography showed no hyper?uores
cence. (c-e) The region corresponding to the area of hyper
?uorescence seen on QDot-CCR3Fab angiography in (b)
contained multiple CD31+ blood vessels in the choroid (Ch)
that were proliferating (Ki67+; arrows) and had not invaded
the retina (Ret). Individual CD31+ (c), and Ki67+ (d), and
merged (e) ?uorescence channel images are shown. Arrows
point to proliferating endothelial cells. Inset shows Ki67+

FIGS. 1011-!) show that CCR3 and VEGF-A do not modu

late each other. (a) Intravitreous administration of anti-CCR3

neutralizing antibody (1 pg) following laser injury in wild
type mice did not change VEGF-A levels in the RPE/ choroid

3 days after injury, compared to isotype control IgG (1 pg)
administration. n:4. (b) Intravitreous administration of anti

VEGF-A neutralizing antibody (2 ng; gray curve) following
laser injury in wild-type mice did not change surface CCR3
expression on CD31+VEGFR-2+ choroidal endothelial cells

CD31+ cells in higher magni?cation. (f) QDot-CCR3Fab

5 days after injury compared to isotype control IgG (2 ng;

hyper?uorescent areas were localized to areas of subretinal

CNV with CCR3+ endothelial cells. (g) The QDot label was
visualized within CD31+ vasculature of subretinal CNV

black curve) administration. SFI, standardized ?uorescence
index (ratio of geometric means of cells exposed to control
IgG (black curve) to cells exposed to anti-VEGF-A antibody

lesions. Images representative of 6 independent experiments.

(gray curve), n:3.

Scale bars, (c-e), 10 pm.

DESCRIPTION OF THE INVENTION

FIG. 5 shows that eotaxins activate Rac-1. Stimulation of

human CECs with CCL11 (10 ng/ml), CCL24 (100 ng/ml), or
CCL26 (2 pg/ml) increased levels of activate Rac-1 GTPase
in human CECs compared to unstimulated (0 s) cells. Equal
amounts (500 pg) of total cell lysates were probed for GTP
bound Rac-1 (active) by pull-down assays. Rac-1 and
GAPDH immunoblotting were also performed using equal
amounts (80 pg) of the original lysates to control for protein

20

eosinophil and mast cell traf?cking (Rothenberg and Hogan
Annu Rev Immunol. 24, 147-174 (2006)), was expressed in
human choroidal endothelial cells (CECs) only in the context

loading. Representative images of 3 independent experiments
are shown.

FIG. 6 shows that CCL11, CCL24, and CCL26 mRNA are
expressed in cultured human RPE cells. Total RNA isolated
from human RPE cells were subjected to RT-QPCR using
speci?c primers for the three eotaxins or ribosomal 18S as
control. Only one band with the predicted size was observed
for each gene, and not in the corresponding negative control

of CNV due to AMD and not in other non-proliferating or
25

ization studies showed that CCR3 was expressed in CECs of

treatment for AMD (FIG. 1a, b). In contrast, CCR3 was not
30

FIGS. 7a-c show that CCR3 does not promote in?amma
tion in mouse CNV model. (a) Laser injury did not recruit
35

Neutralizing anti-CCR3 Ab did not reduce in?ltration of mac

40

phil index refer to the fraction of choroidal cells comprised of
these in?ammatory cells, normalized to value in PBS-treated

eyes, at the peak of their in?ltration (3 days for macrophages
and 1 day for neutrophils).
FIG. 8 shows that CCR3 F(ab) Ab fragment detects CCR3
speci?cally. Thioglycolate-elicited cells obtained from wild
type (WT) and Ccr3 —/— mice were subjected to FACS analy
sis. SSChigh cells were electronically gated and assessed for
SiglecF and CCR3 expression using the indicated antibodies.

Eosinophil percentage (CCR3+/SiglecF+) is depicted in

dal melanoma (0/ 8) (FIG. 1e, f). Collectively these data point

(CCL26) in all examined specimens of surgically excised
CNV tissue from patients with AMD who had received no

prior treatment for AMD (FIG. 1g-j), suggesting that the
eotaxin-CCR3 axis could play a role in this disease state.

Interestingly, despite the abundance of eotaxins, eosinophils
45

and mast cells were not identi?ed in human CNV, consistent

with earlier ?ndings Grossniklaus et al. Arch Ophthalmol.

123, 914-921 (2005).
50

upper right corner of the dot-plot graph. Data are a represen
tative experiment of n:4-6 mice per group. SSC, side scatter.

SiglecF (Sialic acid-binding immunoglobulin-like lectin-F)
is an eosinophil-prominent Siglec. SSCiH and FSH4C
show the cell size and granularity and FLl-H and FL2-H
show the staining intensity of the different antibodies used to
stain cells.

expressed in CECs in the choroid of any patients with early
(atrophic) AMD (0/ 10) or in age-matched patients without
AMD (0/ 10) (FIG. lc, d). CCR3 also was not immunolocal
ized in surgically excised tissue from patients with epiretinal
?brotic membranes (0/ 6) or in CECs in patients with choroi
to a highly speci?c pattern of expression of CCR3
(P:7><10_l4, exact contingency table test) in CECs in neovas
cular AMD. In addition, we identi?ed the expression of the
CCR3 ligands eotaxin-1 (CCL11), -2 (CCL24), and -3

(CCR3i”’CD3_CD117hiCD49d+) into the choroid. 11:8. (b,c)
rophages (Gr-1+F4/80_) 3 days after (b) or of neutrophils
(F4/80+CD11c_) 1 day after (c) into the choroid following
laser injury in wild-type mice. n:6. Macrophage and neutro

proliferating choroidal vasculature (FIG. 1). Immunolocal
all examined specimens of surgically excised CNV tissue
from patients with AMD (18/ 18) who had received no prior

(H20).
eosinophils (CCR3hiCD3_CD117i”’CD49d+) or mast cells

CCR3 Expression Restricted to CNV in Human Eyes
In our studies examining the role of chemokines in angio
genesis, we discovered that CCR3 (also known as CD193), a
chemokine receptor best known for its role in promoting

55

CCR3 Stimulation Promotes CEC Migration and Prolif
eration
The best elucidated pathological functions of CCR3 to date
have been its role in allergic diseases such as asthma (Justice

et al., Am JPhysiol Lung Cell Mol. Physiol. 284, L169-178
(2003); Humbles. et al., Science. 305, 1776-1779 (2004);
Pope et al., J. Immunol. 175, 5341-5350 (2005); Jose et al., J
Exp Med. 179, 881-887 (1994); Teixeira et al., J Clin Invest.

100, 1657-1666 (1997)) and eosinophilic esophagitis (Blan
chard et al., J Clin Invest. 116, 536-547 (2006). There is a

FIG. 9 shows that CCR3 blockade is more effective at

single report of its direct role in angiogenesis Salcedo et al., J.

inhibiting CNV than VEGF-A blockade. A dose-ranging (0.5
ng-1 pg) study determined that the optimal dose of anti

Immunol. 166, 7571 -7578 (2001)). Although eosinophils and

VEGF-A neutralizing antibody (Ab) for inhibiting laser-in
duced CNV in wild-type mice when administered into the
vitreous humor was 2 ng. The peak of CNV inhibition by
VEGF-A neutralization was 57:4% compared to isotype
control IgG, whereas anti-CCR3 neutralizing Ab, at an opti
mal dose of 1 pg, achieved an inhibition of 68:3% (BP<0.05)

compared to isotype control IgG. n:20—25.

60

mast cells have been reported to be involved in angiogenesis

(Puxeddu et al., InZJBiochem Cell Biol. 37, 628-636 (2005);
Heissig et al., J Exp Med. 202, 739-750 (2005)), such actions
are considered minor or isolated. Therefore, we studied the

effects of CCR3 modulation on angiogenesis in vitro and in
65 VlVO.

Neutralizing anti-CCR3 antibodies inhibited the tube for
mation of primary human CECs cultured in Matrigel in vitro
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CCR3-Driven Angiogenesis Uncoupled from In?amma

(FIG. 2a). In an experimental model of CNV induced by laser
injury in wild-type mice (Tobe et al., Am J. Pathol. 153,

tion
We sought to determine whether CCR3 targeting reduced
CNV solely via anti-angiogenic mechanisms or whether anti
in?ammatory mechanisms also were involved. Neither eosi
nophils nor mast cells (de?ned as CCR3hiCD3_

1641-1646 (1998); Nozaki et al. Proc Natl Acad Sci USA.

103, 2328-2333 (2006); Nozaki et al., J Clin Invest. 116,
422-429 (2006); Kleinman et al., Nature. 452, 591-597
(2008); Sakurai et al., Invest Ophthalmol Vis Sci. 44, 3578
3585 (2003); Sakurai et al. Invest Ophthalmol Vis Sci. 44,

CD117””CD49d+ and CCR3””CD3_CD117hiCD49d+ cells,
respectively) were recruited to the choroid following laser

2743-2749 (2003)), neutralizing anti-CCR3 antibodies

injury, as monitored by ?ow cytometry (FIG. 7). Further

reduced the fraction of CECs in vivo that were in the prolif

more, the CNV response in eosinophil-de?cient Adbl GATA

erative state of the cell cycle (FIG. 2b). Consistent with this
?nding, each of the three eotaxins stimulated human CEC

mice (Humbles et al., Science. 305, 1776-1779 (2004) and
mast cell-de?cient KitW'vv/KitW'” mice (Kitamura et al.,

proliferation (FIG. 2c). Cytoskeletal rearrangement through

Blood. 52, 447-452 (1978) was not different from that in

polymerization of monomeric actin to micro?lamentous
F-actin, which is essential for eosinophil chemotaxis induced

wild-type mice (FIG. 3j). In addition, intraocular administra
tion of neutralizing anti-CCR3 antibodies reduced CNV in

by the eotaxins, is also critical in angiogenic migration of

Adbl GATA or KitW'v/KitW'“ mice to the same extent as in

endothelial cells. Stimulation of human CECs with any of the
three eotaxins induced a rapid polymerization of actin mol

ecules (FIG. 2d e). All three eotaxins also activated Rac-l
(FIG. 5), a small GTPase that is critical in regulating endot
helial cell spreading and migration, and promoted human
CEC migration in a dose-dependent fashion (FIG. 2]). Col

wild-type mice. Thus, although eosinophils and mast cells
have been reported to be capable of driving angiogenesis in
20

experimental CNV. Although neutrophil and macrophage

lectively these data demonstrate that CCR3 activation can

promote multiple steps of angiogenesis. The expression of
CCR3 on CECs in vivo is con?ned to CNV tissues; however,

25

in vitro, human CECs responded to CCR3 ligands. Without
wishing to be bound by theory, this might be due to the
presence of several CNV-promoting growth factors in the

F4/80' and F4/80+CD11c_ cells, respectively) (FIG. 7).
30

We studied the in vivo effects of CCR3 targeting in a mouse

model of CNV induced by laser injury (Kleinman et al.,
Nature. 452, 591-597 (2008)), which is the most widely uti
lized animal model of this disease. A single intraocular

35

administration of either CCR3 neutralizing antibodies or a

small molecule CCR3 receptor antagonist ((S)-Methyl-2
naphthoylamino-3-(4-nitrophenyl)propionate) both sup
pressed laser injury-induced CNV in wild-type mice in a
dose-dependent fashion (FIG. 3a-c). CNV was also dimin
ished in Ccr3_/_ mice (Humbles et al., Proc Natl Acad Sci
USA. 99, 1479-1484 (2002)) as compared to wild-type mice

this model is a direct anti-vascular effect and does not appear
to involve modulation of cellular in?ammation. The mecha

nisms underlying the paucity of eosinophils and mast cells in
CNV remain to be de?ned. While not wishing to be bound by
theory, one explanation could be the expression of CXCL9,
which blocks eotaxin-induced CCR3-mediated eosinophil
recruitment (Fulkerson et al., Proc Natl Acad Sci USA. 101,
1987-1992 (2004); Fulkerson et al. Blood. 106, 436-443
(2005) in CNV. Other mechanisms in?uencing adhesion or
mobilization of these leukocytes also might be operative.

CNV Bioimaging by Ccr3 Targeting
40

Because invasion of the retina by CNV results in morpho

logical and functional disruption of the retina, early detection
of CNV is desirable; indeed, detection of CNV before retinal

(FIG. 3d). The speci?city of pharmacological CCR3 block

invasion would be ideal. CNV that has breached the retina can

be detected by ?uorescein angiography. However, this diag

ade was con?rmed by demonstrating that CNV was not

reduced in Ccr3_/_ mice by CCR3 neutralizing antibodies or
CCR3 receptor antagonist (1 16:7% and 109116% of control,

in?ltration are crucial for the development of experimental
CNV (Sakurai et al. (2003) supra; Zhou et al. Mol. Vis. 11,
414-424 (2005), CCR3 receptor targeting did not affect
recruitment of either in?ammatory cell type (de?ned as Gr-1+

Therefore, the angioinhibitory effect of CCR3 blockade in

culture medium.

CCR3 Receptor or Ligand Antagonism Inhibits CNV

other systems (Puxeddu et al., Int J Biochem Cell Biol. 37,
628-636 (2005); Heissig et al., J Exp Med. 202, 739-750
(2005), both cell types are dispensable in the development of

45

respectively; n:5; P>0.1). CCL-l 1 and CCL-24, the principal

nostic modality cannot detect CNV before it has invaded the
retina, i.e., when it is still limited to the choroid. Yet postmor
tem histopathological studies have shown that substantial

mouse ligands for CCR3, were markedly increased soon after

numbers of patients in whom ?uorescein angiography does

laser injury and immunolocalized to the retinal pigmented

not reveal the presence of CNV nevertheless have CNV that

epithelium (RPE), which is adjacent to CECs (FIG. 3e, j).

50

Also, human RPE cells synthesized all three eotaxins (FIG.
6), implicating these cells, which are abundantly interspersed
in CNV (Grossniklaus et al. Arch Ophthalmol. 123, 914-921

Ophthalmol Soc. 75, 180-254 (1977). Therefore, we explored
whether CCR3-targeted bioimaging using anti-CCR3 Fab
antibody fragments (FIG. 8) conjugated to quantum dots
(QDot-CCR3 Fab) could detect CNV before it became clini

(2005)), as a source of CCR3 ligands in CNV. Genetic abla

tion of either Cc111 (Rothenberg, et al., J Exp Med. 185,
785-790 (1997)) or Ccl24 (Pope et al., J Immunol. 175,
5341-5350 (2005) reduced CNV, while the neovascular
response in Cc111_/_><Ccl24_/_ mice (Pope et al. (2005)

55

CNV in senescent mice de?cient in monocyte chemoattrac

60

occurs at a younger age in Ccl2_/_><Ccr2_/_ mice (unpub

65

lished data). These mice also undergo outer retinal degenera
tion rapidly. We tested whether fundus angiography follow
ing intravenous injection of QDot-CCR3 Fab could detect
subretinal CNV in these mice. QDot-CCR3 Fab angiography
demonstrated hyper?uorescent signals in regions of the fun

these two ligands in this system (FIG. 3g). A single intraocu
lar administration of neutralizing antibodies against CCL-ll
or CCL-24 also suppressed CNV in wild-type mice (FIG. 3h,
i), validating these CCR3 ligands as anti-angiogenic targets.
Together, these data demonstrate that CCR3 activation is
essential for in vivo angiogenesis in the most widely used
preclinical model of neovascular AMD.

cally evident.
We previously described the spontaneous development of
tant protein-1 (MCP-l/CCL-2) or its CCR2 receptor (Ambati
et al., Nat. Med. 9, 1390-1397 (2003)). Similar pathology

supra) was suppressed to a greater extent than in either of the

“single knockout” mice, suggesting cooperation between

has not yet invaded the retina (Green and Key, Trans Am

dus of these mice that were silent on ?uorescein angiography

(FIG. 4a, b). The speci?city of CCR3 targeting was con?rmed
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by the absence of hyper?uorescent signals in Ccl2_/_><
Ccr2_/_ mice injected with QDot-isotype Fab and in wild
type mice injected with QDot-CCR3 Fab (FIG. 4b). Histo

289, 1197-1202 (2000); Zhang et al., Science 276, 1268-1272
(1 997)) however, CCR3 has not been identi?ed in any of these
reports. Therefore, our studies identify CCR3 as a novel

logical examination of these areas revealed proliferating
(Ki67+) CCR3+ blood vessels in the choroid that had not yet

marker of pathological angiogenesis and as a functional target
in neovascular AMD.
Thus, an aspect of this invention is a method for detecting
subclinical CNV comprising contacting the choroid of a sub
ject with an agent that speci?cally binds to CCR3 or to
eotaxin 1, 2 or 3, and then assaying the choroid for binding of
the agent to vessels in the choriod, wherein binding of the
agent to vessels in the choroid is indicative of subclinical
CNV. Subclinical as used herein refers to subjects who do
have CNV invasion of the retina. Agents that speci?cally bind

invaded the retina, along with accumulation of QDot-CCR3
Fab in these vessels (FIG. 4c-e). These data demonstrate that
CCR3-targeted bioimaging can detect subclinical CNV
before it disrupts the retina and causes vision loss.

CCR3 Targeting Superior to VEGF-A Targeting
In comparing CCR3 targeting to VEGF-A targeting, the
mo st effective approved treatment for human CNV, we found
that CCR3 neutraliZing antibodies were more effective than

VEGF-A neutraliZing antibodies (68:3% vs. 57:4%) at
inhibiting laser-induced CNV in mice (FIG. 9). In the laser
injury model, CCR3 neutralization did not change VEGF-A

to CCR3 or to eotaxin 1, 2 or 3 include, e.g., CCR3- or

eotaxin-speci?c antibody or antibody fragments, eotaxins 1,
2, or 3 and fragments of eotaxin 1, 2 or 3 that bind to CCR3;
or peptides or aptamers that speci?cally bind to CCR3 or
eotaxin 1, 2 or 3; or a CCR3-speci?c small molecule inhibitor,

levels in the RPE/choroid and VEGF-A blockade did not

change CCR3 expression on CECs (FIG. 10): these two path
ways appear to be not directly coupled. Repeated intravitre
ous administration of anti-VEGF-A antibodies resulted in

see for example US. Publication No. 20070190055 for a
20

anatomic and functional damage to the retina in wild-type
mice, consistent with earlier reports that anti-VEGF-A
therapy induces dysfunction in and damage to the inner and

6,207,155, and in US. published applications 20050191702,

outer murine retina6’7. These effects were modest at a dose of

anti-VEGF-A antibodies that suppressed mouse CNV but
more pronounced at a higher dose that is comparable to the
dose used in humans. It should be noted that anti-VEGF-A
pharmacotherapy has not been associated with an increased

risk of profound retinal damage in humans (Ip et al., Ophthal
mology. 115, 1837-1846 (2008), but subtle abnormalities
have been observed (Sayanagi et al., Br]. Ophthalmol. Feb
ruary 10 [Epub ahead of print] (2009); Yodoi et al. Am J.
Ophthalmol. 147, 816-824 (2009)) and some adverse effects
might be misattributed to disease progression. In contrast to
VEGF-A blockade, neither CCR3 Ab nor CCR3 receptor
antagonist induced retinal toxicity in wild-type mice as con

25

20050069955, and 20020147312 for exemplary antibodies
which speci?cally bind and inhibit the CCR3 receptor and
US. Pat. Nos. 6,946,546 and 6,635,251, and in US. pub
lished applications 20040191255 and 20040014132 for
exemplary antibodies, which speci?cally bind and inhibit
eotaxin and eotaxin-2.

30

35

Antibodies and antibody fragments speci?c for CCR3 or
eotaxins can be generated using any number of techniques
well-known in the art. For example, for preparation of mono
clonal antibodies, any technique which provides for the pro
duction of antibody molecules by continuous cell lines in
culture may be used. For example, the hybridoma technique

originally developed by Kohler and Milstein (Nature 256:

?rmed by fundus imaging and electrophysiological function.
Vegfa deletion is embryonically lethal (Carmeliet et al.,
Nature. 380, 435-439 (1996); Ferrara et al., Nature. 380,
439-442 (1996)) and conditional ablation ofVegfa in the RPE

description of numerous small molecule inhibitors for the
CCR3 receptor have been developed and can be used in the
present invention. See also US. Pat. Nos. 6,806,061 and

495-497 (1975)), as well as the trioma technique, the human

B-cell hybridoma technique (Kozbor et al., Immunology
Today 4:72 (1983)), and the EBV-hybridoma technique to
40

induces profound retinal degeneration and visual dysfunction

produce human monoclonal antibodies (Cole et al., in
“Monoclonal Antibodies and Cancer Therapy,” Alan R. Liss,

(Marneros et al., Am J. Pathol. 167, 1451-1459 (2005). In

Inc. pp. 77-96 (1985)) and the like are within the scope of the

contrast, the Ccr3_/_ mouse retina was normal in appearance

present invention.

and electrophysiological function.
Discussion

45

The monoclonal antibodies for therapeutic use may be
human monoclonal antibodies or e.g., chimeric human

CCR3 targeting is useful for early detection (using bio
compatible quantum dots or other bioimaging ?uorochromes

mouse (or other species) monoclonal antibodies. Human
monoclonal antibodies may be made by any of numerous

such as near infrared dyes) and treatment of CNV (by receptor
or ligand targeting) superior to current standard of care.

techniques known in the art (e.g., Teng et al., (1983) Proc.
Natl. Acad. Sci. USA. 80:7308-7312; KoZbor et al., (1983)

tary disturbances and multiple subretinal lipoproteinaceous

Immunology Today 4:72-79; Olsson et al., (1982) Meth. Enzy
mol. 9213-16). Chimeric antibody molecules may be prepared

deposits known as drusen or fellow eye involvement with

containing a mouse antigen-binding domain with human con

clinically evident CNV, as they are known to be at high risk

stant regions (Morrison et al., (1984) Proc. Natl. Acad. Sci.
USA. 8116851, Takeda et al., (1985) Nature 314:452). Vari

CCR3 bioimaging is useful in individuals with RPE pigmen

for developing CNV (Bressler et al., Arch Ophthalmol. 108,
1442-1447 (1990); Maguire et al. Arch Ophthalmol. 115,

50
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741-747 (1997). Similar techniques are also useful in non

invasively bioimaging other metabolic or molecular markers
to provide information about disease pathogenesis or activity.
For example, metabolic or molecular markers in tissues of the
eye can be detected by contacting the tissue with an agent
speci?c for that metabolic or molecular marker wherein the
agent is labeled with a NIRF or Qdot and the label is detected

60

etc. A molecular clone of an antibody to a CCR3 epitope can

be prepared by known techniques. Recombinant DNA meth
odology (see e.g., Maniatis et al., 1982, Molecular Cloning,A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold

by using angiography techniques that are well-known in the

Spring Harbor, NY.) may be used to construct nucleic acid

art.

Several strategies have yielded molecular markers that are

ous procedures known in the art may be used for the produc
tion of polyclonal antibodies to epitopes of CCR3. For the
production of antibody, various host animals can be immu
nized by injection with CCR3 protein, or fragment or deriva
tive thereof, including but not limited to rabbits, mice, rats,

65

sequences which encode a monoclonal antibody molecule, or

preferentially expressed on proliferating endothelial cells

antigen binding region thereof. such fragments include but

such as those in tumor vasculature (St Croix et al., Science

are not limited to: the F(ab')2 fragment which can be produced
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by pepsin digestion of the antibody molecule; the Fab' frag

behavior and resultant MRI contrast. See also U.S. Publica

ments which can be generated by reducing the disul?de

tion No. 20070269382 for a description of nanoparticles and
their use for multifunctional bioimaging.
Another aspect of this invention is a method for treating
CNV in a subject in need thereof comprising administering to

bridges of the F(ab')2 fragment, and the Fab fragments which
can be generated by treating the antibody molecule with
papain and a reducing agent. See also, e.g., Cabilly et al., U.S.
Pat. No. 4,816,567; Cabilly et al., European Patent No. 0, 125,

the subject a CCR3 antagonist in an amount suf?cient to

inhibit progression of CNV. “Treating CNV in a subject”
includes e.g., stopping, slowing or reversing the progression
of CNV in the subject. In one aspect of the invention the retina
of the subject is not invaded by CNV but CNV is detected in
the choroid, e.g., CCR3 expression is detected in vessels in
the choroid. The CCR3 antagonist may be, e.g., a CCR3

023. B1; Boss et al., U.S. Pat. No. 4,816,397; Boss et al.,

European Patent No. 0,120,694 B1; Neuberger, M. S. et al.,
WO 86/01533; Neuberger, M. S. et al., European Patent No.
0,194,276 B1; Winter, U.S. Pat. No. 5,225,539; and Winter,
European Patent No. 0,239,400 B1. See also, Newman, R. et

al., BioTechnology, 10: 1455-1460 (1992), regarding prima

neutraliZing antibody or CCR3 neutraliZing antibody frag

tized antibody, and Ladner et al., U.S. Pat. No. 4,946,778 and
Bird, R. E. et al., Science, 242: 423-426 (1988)) regarding

ment or a peptide that competes with a natural ligand for
binding to CCR3 or a peptide or low molecular weight com

single chain antibodies.

pound having activity which inhibits binding of CCR3

The agent may be conjugated to a detectable label. A
detectable label is a moiety, the presence of which can be
ascertained directly or indirectly. The detectable label may
be, e. g., a radioisotope, a bioimaging ?uorochrome, a contrast
agent, or a gaseous agent. The agent may be e.g., a ?uores

ligands to CCR3 on target cells. The CCR3 antagonist may
also be a peptide that speci?cally binds to CCR3, wherein the
peptide is conjugated to toxin or cytostatic agent that kills or
inhibits the growth of cells expressing CCR3. The CCR3
neutraliZing antibody fragment may be e. g., a CCR3-speci?c

20

cently labeled CCR3-speci?c antibody or antibody fragment,

Fab. The CCR3-speci?c antibody or antibody fragment may

e.g., a CCR3-speci?c Fab or CCR3 speci?c peptide or

be conjugated to a compound suitable for bioimaging, e.g.,

aptamer. The agent may be conjugated to a bioimaging ?uo

bioimaging ?uorochrome such as a near-infrared ?uorophore
(“NIRF”) or quantum dot.
A subject in need thereof may be a subject at risk for

rochrome, e.g., a near infrared dye or semiconductor nanoc

rystals “quantum dots” and iron oxide nanocrystals. Those of

25

ordinary skill in the art will know of suitable labels for bind
ing to the agents used in the methods described herein, or will

be able to ascertain such, using routine experimentation. The
coupling of these labels to the agents used in the methods of
the invention may be accomplishedusing standard techniques
well-known to those of ordinary skill in the art. For example,
nanoparticle probes have been used as labels in biological
systems and for bioimaging (Akerman et al., Proc Natl Acad
Sci USA 2002, 99:12617; Santra et al.,Analytical Chemistry,
2001, 73:4988; Santra et al., Journal ofBiomedical Optics,
2001, 6:160; Ben-Ari et al., Journal ofthe National Cancer
Institute, 2003, 95:502; Panyam et al., International Journal

of Pharmaceutics, 2003, 262:1); diagnostic (Brigger et al.,
Adv Drug Deliv Rev, 2002, 54:631; Alivisatos, Scientific
American, 2001, 285:66), and therapeutic purposes (Emerich
et al., Expert Opinion on Biological Therapy 2003, 3:655;
Douglas et al., Crc Critical Reviews in Therapeutic Drug
Carrier Systems, 1987, 3:233; Holm et al., Molecular Crys
tals and Liquid Crystals, 2002, 374:589). Diagnostic neu
roimaging techniques such as angiography, CT (computed

age related macular degeneration or an individual with RPE

pigmentary disturbances, multiple subretinal lipoproteina
30

subject at risk for developing or suspected of having choroi
cally binds to CCR3 or to eotaxin 1, 2 or 3, or the CCR3
35

ally, intranasally, orally, subcutaneously, intraperitoneally, or
40

to detect CCR3 on choriod vessels or to inhibit CNV progres
sion.

The invention also relates to a method for evaluating the
risk of a subject for developing retinal CNV. In one aspect of

the invention, a subject is assayed for CCR3 expression in
45

choroid vessels, wherein expression of CCR3 in choriod ves
sels is indicative of choridal CNV or an elevated risk for

developing retinal CNV. In another aspect of this invention,
the level of CCR3 expression is compared to the expression
level in the choroid of subjects who are not at risk for devel
50

oping or suspected of having choroidal neovascularization
Also an aspect of this invention is a method for assaying a

pre-selected agent for inhibition of choroid CNV in a subject

comprising detecting expression of CCR3 in the choroid of
the subject by bioimaging before and after treatment with an
agent and comparing expression levels or localization of
55

raphy and CT scans are radio-opaque, which allow clear
visualization of the contrast under an X-ray source. Iodinated

chemical compounds such as iohexyl (also called

CCR3 in the choroid before and after treatment, wherein a
reduction in CCR3 expression in the choroid or a change in
the localization of CCR3 in the choroid is indicative of inhi

bition of CNV by the agent. The subject may e.g., have CNV
in the choroid and/or the retina of the subject may also have

OMNIPAQUETM) and iodixanol (also called VISIPAQUETM)
are routinely used as X-ray contrast agents. They consist of

speci?c antagonist may be administered systemically or
locally. For example, the agent or CCR3-speci?c antagonist
may be administered intravenously, intrathecally, intraarteri
by local injection or surgical implant in an amount suf?cient

agents are often administered to patients, to help delineate

pathological from healthy tissue. Contrast agents for angiog

ceous deposits or fellow eye involvement with clinically evi
dent CNV. In one aspect of the invention, the retina of a

dal neovascularization is not invaded by CNV.
In the methods of this invention the agent which speci?

tomography) and MRI are well-known and widely used to

monitor changes in anatomy and disease diagnosis (Hilde
brandt et al., Clinical Immunology, 2004, 111:210; DZik
JurasZ et al., British Journal ofRadiology, 2004:77, 296;
Costouros et al., Journal of Cellular Biochemistry, 2002:72;
Langer et al., World Journal ofSurgery, 2001, 25: 1428; Smith
et al., Journal ofNeurotrauma, 1995, 12:573; Kreel et al.,
Postgraduate Medical Journal, 1991, 67:334). Contrast

developing or suspected of having choroidal neovasculariza
tion. The subject may be e. g., a subject at risk for developing

60

CNV.

electron dense iodine atoms, which show contrast under an

EXAMPLES

X-ray. MRI contrast agents such as Gadoteridol, (Gd-HP
DO3A, a gadolinium chelate complex, also known as PRO

HANCETM) and mangafodipir trisodium (a manganese che
late complex, also known as TESLASCANTM) are usually
paramagnetic. Both gadolinium and manganese atoms con

tain unpaired electrons, which account for paramagnetic

Methods
65

Mouse model of CNV. Laser photocoagulation (OcuLight
GL, Iridex Corporation) was performed on mouse eyes to
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induce CNV, and CNV volumes were measured 7 days after

Leica) as previously described (Kleinman, et al., Nature. 452,

(5 pg; R&D Systems), control goat IgG (Jackson Immunore
search), or (S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)
propionate (SB328437; Calbiochem) dissolved in DMSO

591-597 (2008)). Drug injections. Rat IgG2a neutralizing

were injected into the vitreous humor of mice using a

antibody against mouse CCR3 (R&D Systems), control rat

IgG2a (Serotec), goat neutralizing antibody against mouse
CCL11 (R&D Systems), goat neutralizing antibody against

33-gauge double-calibre needle (Ito Corporation) once,
immediately after laser injury as previously described (Klein
man, et al., (2008) supra).

mouse CCL24 (R&D Systems), control goat IgG (Jackson
Immunoresearch), or (S)-Methyl-2-naphthoylamino-3-(4-ni

(1:250; Santa Cruz) coupled with PE-donkey antibody

injury by scanning laser confocal microscope (TCS SP,

trophenyl)propionate (SB328437; Calbiochem) dissolved in

Flow cytometry. Rat antibody against mouse CCR3
10

DMSO were injected into the vitreous humor using a

33-gauge double-calibre needle (Ito Corporation) once,
immediately after laser injury as previously described (Klein
man, et al., (2008) supra).
CCR3 bioimaging. F(ab) fragments were created from
monoclonal IgG2a antibody raised against the extracellular

against rat IgG (1:250; Jackson Immunoresearch) or Alex
aFluor647-conjugated rat antibody against mouse CCR3 (10
pg/ml; BD Biosciences) were used to quantify cell surface
receptor expression on choroidal endothelial cells, de?ned by

CD31+ VEGFR-2+ expression, gated by FITC-conjugated rat
antibody against mouse CD31 (20 pg/ml; BD Biosciences)
and PE-conjugated rat antibody against mouse VEGFR-2 (20

domain of murine CCR3 (R&D Systems) and an isotype rat

pg/ml; BD Biosciences). Macrophages, neutrophils, eosino

IgG2a (R&D Systems) using a commercially available
papain-based kit (Pierce). Recovered fragments were conju

phils and mast cells were de?ned as F4/80+CD11c_, Gr-l+

gated with quantum dots (Invitrogen, QDot-800) and resus

20

F4/80‘, CCR3’”CD3‘CD117””CD49d+ and CCR3i”’CD3_
CD117hiCD49d+ cells, respectively. DNA content for cell

pended in sterile PBS. Ccl2_/_><Ccr2_/_ mice were adminis
tered 100 pg of tagged CCR3 F(ab) or isotype F(ab) via tail

cycle was analyzed after incubation with propidium iodide

vein injection after acquiring baseline ?uorescent imaging

X-100 and RNase A (0.1 mg/ml; Roche). Samples were ana
lyzed on a LSRII (Becton Dickinson).
Immunolabeling. Immuno?uorescent staining was per
formed with antibodies against human CCR3 (rat mono
clonal, R&D Systems) or human CD31 (mouse monoclonal,
Dako) and identi?ed with Alexa 488 (Molecular Probes) or

(0.05 mg/ml; Molecular Probes) containing 0.1% Triton

using a Topcon retinal camera (TRC-501X). Serial images
were then acquired at 1, 4, and 12 h after which eyes were

25

harvested and frozen in OCT for immuno?uorescent analy

ses. Retinal images were analyzed (ImageNet, Topcon) by
comparison to baseline and ?uorescein angiographic data.
Hyper?uorescent areas were then cropped, equally thresh

olded, and pseudocolored (Photoshop CS3, Adobe). Sections

Cy3 secondary antibodies (Jackson ImmunoResearch).
30

Immunohistochemical staining with the primary antibodies
speci?c for human eotaxins-1, 2 and 3 (mouse monoclonal,

from QDot-conjugated CCR3 or rat IgG2a isotype F(ab)
injected animals were ?xed in 4% paraformaldehyde and

R&D Systems) was performed using horseradish peroxidase.

blocked with 5% normal donkey serum/5% goat serum in

Laser injured mouse eye sections were stained with antibod

PBS, stained with rat anti-mouse CD31 (BD Biosciences) and
either rabbit anti-mouse CCR3 (Santa Cruz) or rabbit anti

ies against mouse CCL11 or CCL24 (both R&D Systems)
35

Ki67 (Abcam) followed by appropriate ?uorescent secondary
antibodies (Alexa Fluor 488/594, Invitrogen), and evaluated
by confocal laser scanning microscopy (Leica SP-5).
Methods
Human tissue. Choroidal neovascularization (CNV) tissue

and visualized with FITC or Cy3 secondary antibodies.
Images were obtained using Leica SP5 or Zeiss Axio

Observer Z1 microscopes.
Tube formation assay. 96-well plates were coated with
40

was excised from patients with age-related macular degen
eration (AMD) who had no prior treatment for CNV. Retinal
?brosis tissue was excised from patients with a diagnosis of

epiretinal membrane formation. Donor eyes from patients
with atrophic AMD without CNV and patients without AMD

45

were obtained from eye banks. Eyes with choroidal mela
noma were obtained by surgical enucleation. The study fol
lowed the guidelines of the Declaration of Helsinki. Institu
50

C57BL/6J and KitW'v/KitW'“ mice were purchased from The
55

Ccl24_/_, and Adbl GATA mice have been previously
described (Humbles et al., Science. 305, 1776-1779 (2004);
60

Systems), goat neutralizing antibody against mouse CCL24

in MCDB131 media (Gibco) with 0.1% FBS. They were
passaged to 96-well plates at a density of 5,000 cells per well,
followed by stimulation for 24 h with eotaxin-1, 2 or 3 (10 ng,
100 ng and 2 pg per ml, respectively; Peprotech) in
MCDB131 media with 0.1% PBS. After 24 h, cell viability
was measured with BrdU ELISA (Chemicon) according to
manufacturer’ s instructions.

F-actin Polymerization Assay. Human CECs were seeded
in black-walled 96-well plates and grown to 70-80% con?u

(2003)).
Drug injections. Rat IgG2a neutralizing antibody against
mouse CCR3 (R&D Systems), control rat IgG2a (Serotec),
goat neutralizing antibody against mouse CCL1 1 (1 pg; R&D

Proliferation assay. Human CECs were synchronized for

cell cycle state by ?rst cultivating them in EGM2-MV media
(Lonza) supplemented with 10% FBS (Gibco) to achieve
complete con?uence and then by overnight serum starvation

the guidelines of the University of Kentucky IACUC and the
Association for Research in Vision and Ophthalmology.

Pope et al. J. Immunol. 175, 5341-5350 (2005); Humbles et al.
Proc NazlAcad Sci USA. 99, 1479-1484 (2002); Rothenberg
et al., J Exp Med. 185, 785-790 (1997)). Ccl2_/_><Ccr2_/_
mice were generated by interbreeding “single knockout”
mice described previously (Ambati et al., Med. 9, 1390-1397

allowed to solidify in the incubator at 37° C. for 45 min.
Human choroidal endothelial cells (CECs)44_47 were plated
on top of the Matrigel at 2.25><104/cm2 in EBM-2 basal media
(Cambrex) containing 1% PBS with CCR3 antibody or rat
IgG2a at the above concentrations and allowed to grow over

Animals. All animal experiments were in accordance with

Jackson Laboratory. Ccr3_/_, Cc111_/_, Ccl24_/_, Cc111_/_><

Growth Factor Reduced Matrigel (BD Biosciences) mixed
with rat neutralizing antibody against human CCR3 (20
pg/ml, R&D Systems) or control rat IgG2a (Invitrogen) and

night. Tube formation was analyzed by counting the number
of cell junctions per m2.

tional review boards granted approval for allocation and

histological analysis of specimens.

along with antibody against mouse CD31 (BD Biosciences)

ence in fully supplemented EGM-2MV. Cultures were serum

starved overnight in basal media and then stimulated with
65

recombinant human eotaxin-1 (10 ng/ml), eotaxin-2 (100
ng/ml), eotaxin-3 (2 pg/ml) (Peprotech), or vehicle control
(PBS). At 0, 10, 30, 60, or 120 sec time-points, cells were

US 8,778,616 B2
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?xed in 3.7% paraforrnaldehyde for 10 min, washed, perme

tions can be made therein without departing from the sprit and

abilized in PBS with 0.1% Triton-X, and then stained with
rhodamine labelled Phalloidin (1:200, lnvitrogen) per manu

scope thereof. All such variations and modi?cations are
intended to be includedwithin the scope of this disclosure and

the present invention and protected by the following claims.

facturer’s recommendations. Plates were analyzed on a ?uo

We claim:
1. A method for detecting subclinical choroidal neovascu
larization (“CNV”) comprising contacting a choroid with an

rescent plate reader (Synergy 4, Biotek) followed by ?uores
cent microscopy (Nikon E800).
Migration Assay. Eotaxins-l, -2, -3 were reconstituted in

agent that speci?cally binds CCR3 and assaying the choroid
for binding of the agent to vessels in the choroid, wherein

0.1% bovine serum albumin (BSA) and then mixed with
Matrigel diluted 1:1 with serum free endothelial basal media
(EBM-2; Lanza). 500 pl of EBM-2 was added to each well of
a 24-well plate followed by a 6.5 mm diameter Transwell
insert (8 pm pores; Corning). Human CECs in EBM-2 were

binding of the agent to vessels in the choroid is indicative of
subclinical CNV.
2. The method of claim 1 wherein the agent is a CCR3

speci?c antibody; a CCR3-speci?c antibody fragment;

prestained witthbrant DiO (lnvitrogen) for 30 min at 370 C.

eotaxin 1, eotaxin 2 or eotaxin 3; a fragment of eotaxin 1,

and seeded into the inserts at 50,000 cells per 200 pl of serum
free EBM-2 media. The plates were allowed to incubate for
16 h at 370 C., 5% C02. The migrated cells were imaged with
an Olympus CK40 microscope and Olympus DP71 camera.

eotaxin 2 or eotaxin 3 that binds to CCR3; a peptide or

aptamer that speci?cally binds to CCR3, eotaxin 1, eotaxin 2
or eotaxin 3; or a CCR3-speci?c small molecule inhibitor.

3. The method of claim 2 wherein the agent is conjugated to

Rac-l activation. Human CECs were cultured in EGM-2

a detectable label.

MV containing 5% FBS. Prior to starting the assay, cells were

serum starved with basal medium (MCDB13 1) supplemented
with 1% FBS overnight. Cells were stimulated for designated
times with Eotaxin-l, 2 and 3 (10 ng/ml, 100 ng/ml and 2

20

chrome is a near infrared dye or quantum dot.
6. The method of claim 1 wherein the agent is a detectable

pg/ml respectively). Equal amounts of lysates (500 pg) were
incubated with GST-Pakl-PBD agarose beads (Upstate) to
pull-down active GTP-bound Rac-l at 4° C. for 1 h with

25

body fragment is a CCR3-speci?c Fab.
8. The method of claim 7 wherein the CCR3-speci?c Fab is
conjugated to a bioimaging ?uorochrome.

(Upstate).
Electroretinography. Mice were dark adapted overnight
30

ColorBurst Ganzfeld stimulator (Diagnosys). Espion soft

reference to the same extent as if each reference had been

incorporated by reference in its entirety individually.
While the invention has been described in detail and with

reference to speci?c embodiments thereof, it will be apparent
to one skilled in the art that various variations and modi?ca

9. The method of claim 1 wherein the choroid is in or from

a subject at risk for developing or suspected of having chor
oidal neovascularization.
10. The method of claim 9 wherein the subject is a subject

ware (Diagnosys) was used to program a fully automated
?ash intensity series from which retinal responses were

recorded.
All references cited in this disclosure are incorporated by

CCR3-speci?c antibody or antibody fragment.
7. The method of claim 6 wherein the CCR3-speci?c anti

rotation. The samples were subsequently analyzed for bound
Rac-l by western blot analysis using an anti-Rac-l antibody
and then anesthetized. Both eyes were positioned within a

4. The method of claim 2 wherein the label is a bioimaging
?uorochrome.
5. The method of claim 4 wherein the bioimaging ?uoro

at risk for developing age-related macular degeneration.
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11. The method of claim 9 wherein the subject is an indi

vidual with retinal pigmented epithelium (“RPE”) pigmen
tary disturbances, multiple subretinal lipoproteinaceous
deposits or fellow eye involvement with clinically evident
CNV.

